abstract
- Writing Committee for the REMAP-CAP Investigators; Higgins AM, Berry LR, Lorenzi E, et al. Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. JAMA. 2023;329:39-51. 36525245.
In critically ill patients with COVID-19, IL-6 receptor antagonists reduced mortality vs. control at 180 d
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
authors
status
publication date
- April 2023
has subject area
- 1103 Clinical Sciences (FoR)
- 1117 Public Health and Health Services (FoR)
- COVID-19 (MeSH)
- Critical Illness (MeSH)
- Humans (MeSH)
- Randomized Controlled Trials as Topic (MeSH)
- Receptors, Interleukin-6 (MeSH)
published in
- ACP journal club Journal